The company’s strategic pivot centers on leveraging artificial intelligence to expedite the development of its heart attack detection platform. This shift is accompanied by a broader push for global integration, with plans to partner with governments, health systems, and manufacturing entities to ensure widespread adoption.

Despite the leadership change, the firm remains committed to its previously announced clinical studies. Vajdic emphasized that these trials are essential to validating the platform’s performance as it expands into more complex cardiac diagnostics, seeking to establish the technology as a reliable standard for emergency heart monitoring.